570PTreatments (tx) after progression to first-line...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

570PTreatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO

Rossini, D, Lonardi, S, Antoniotti, C, Santini, D, Tomasello, G, Aprile, G, Moretto, R, Prete, A A, Granetto, C, Urbano, F, Borelli, B, Zaniboni, A, Randon, G, Buonadonna, A, Ritorto, G, Barbara, C, L
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz246.047
Date:
October, 2019
File:
PDF, 85 KB
2019
Conversion to is in progress
Conversion to is failed